TA 46

Drug Profile

TA 46

Alternative Names: TA-46

Latest Information Update: 27 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therachon
  • Class Proteins
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Achondroplasia

Most Recent Events

  • 09 Aug 2018 Therachon plans clinical trial for Achondroplasia (In children) in 2019
  • 21 Jun 2018 Therachon plans to file clinical trial applications in early 2019
  • 14 Feb 2018 Phase-I clinical trials in Achondroplasia (In adolescents, In children, In volunteers) in Netherlands (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top